Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.727
Index Copernicus  – 152.95 pts
MNiSW – 40 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 6, November-December, p. 743–749

Publication type: original article

Language: English

Seropositivity for Chlamydophila pneumoniae is Associated with Increased Body Mass Index and Serum Lipid Levels: Evidence from the Sample Urban Population in Bydgoszcz

Wpływ zakażeń Chlamydophila pneumoniae na wskaźniki otyłości i gospodarki lipidowej u osób dorosłych z terenu Bydgoszczy

Agnieszka Jaworowska1,, Grzegorz Bazylak1,, Eugenia Gospodarek2,

1 Department of Bromatology and Molecular Nutrition, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

2 Department of Microbiology, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

Abstract

Background. Although it is well known that obesity is a multifactoral disease, the possibility that some viruses or bacteria might be a serious etiologic factor in this metabolic disorder has received relatively little attention.
Objectives. As no information is available on a link between Chlamydophila pneumoniae infections and the prevalence of obesity in Poland, this study was conducted to provide such pilot data from a sample of professionally active adults randomly recruited from an urban area in Bydgoszcz.
Material and Methods. Anthropometric measurements were obtained from 39 healthy middle−aged adult subjects (4 male, 35 female) of whom 27 were obese or overweight. Antibody status (IgG, IgA, IgM) was determined by enzyme−linked immunosorbent assay (ELISA). The total cholesterol (TChol) and triglyceride (TG) concentrations in serum were performed by standard enzymatic methods.
Results. The group of subjects with IgG antibodies for C. pneumoniae was characterized by higher BMI (31.4 ± 5.5 vs. 27.4 ± 6.3 kg/m2, p = 0.038), higher serum TChol (5.64 ± 0.91 vs. 5.02 ± 0.81 mmol/l, p = 0.047), and higher TG level (1.38 ± 0.34 vs. 1.16 ± 0.49 mmol/l, p = 0.047) than seronegative subjects. Seropositivity for C. pneumoniae IgA antibodies was associated with higher serum TChol concentration (5.91 ± 0.67 vs. 5.15 ± 0.93 mmol/l, p = 0.007). No subjects were positive for IgM antibodies.
Conclusion. The results of this pilot study indicate that C. pneumoniae infection is associated with higher body mass index and elevated serum lipid concentrations in a sample of a middle−aged adult urban population from Bydgoszcz.

Streszczenie

Wprowadzenie. Otyłość jest jednostką chorobową o złożonym i wieloczynnikowym podłożu, możliwość jednak udziału czynnika infekcyjnego w etiologii otyłości była rzadko rozważana, a w Polsce nie podejmowano dotychczas tego problemu.
Cel pracy. Określenie współzależności między obecnością w surowicy przeciwciał swoistych dla Chlamydophila pneumoniae a występowaniem otyłości i gospodarką lipidową aktywnych zawodowo osób dorosłych stanowiących próbkę populacji wielkomiejskiej z terenu Bydgoszczy.
Materiał i metody. W grupie 39 dorosłych osób w średnim wieku (w tym 27 z nadwagą lub otyłością) objętych badaniami przeprowadzono pomiary antropometryczne. Stężenie cholesterolu całkowitego (TChol) i triglicerydów (TG) w surowicy badanych osób oceniono z zastosowaniem metody enzymatycznej. Do oznaczenia obecności przeciwciał klasy IgG, IgA, IgM dla C. pneumoniae wykorzystano metodę immunoenzymatyczną.
Wyniki. Odnotowano, że osoby ze stwierdzoną obecnością przeciwciał klasy IgG charakteryzowały się statystycznie istotnie wyższym BMI (31,4 ± 5,5 vs. 27,4 ± 6,3 kg/m2; p = 0,038) oraz stężeniem TChol (5,64 ± 0,91 vs. 5,02 ± ± 0,81 mmol/l; p = 0,047) i TG (1,38 ± 0,34 vs. 1,16 ± 0,49 mmol/l; p = 0,047) w surowicy niż osoby seronegatywne. Wykazano również, że obecność w surowicy przeciwciał klasy IgA jest związana z istotnie większym stężeniem TChol (5,91 ± 0,67 vs. 5,15 ± 0,93 mmol/l; p = 0.007). Nie stwierdzono obecności przeciwciał klasy IgM w badanej grupie osób z terenu Bydgoszczy.
Wnioski. Uzyskane wstępne wyniki wskazują na duże prawdopodobieństwo udziału czynnika infekcyjnego w etiologii nadwagi i otyłości. Wykazano również współzależność między obecnością przeciwciał swoistych dla C. pneumoniae a profilem lipidowym w surowicy badanych osób z terenu Bydgoszczy.

Key words

Chlamydophila pneumoniae, infectobesity, BMI, serum cholesterol, serum triglycerides

Słowa kluczowe

Chlamydophila pneumoniae, BMI, otyłość, nadwaga, cholesterol całkowity, triglicerydy, surowica

References (33)

  1. WHO Technical Report Series: Obesity, preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva, 2000, 894, 1–253.
  2. James PT, Leach R, Kalamara E, Shayeghi M: The worldwide obesity epidemic. Obes Res 2001, 9, 228S–223S.
  3. Hlubik P, Opltova L, Chaloupka J: Prevalence of obesity in selected subpopulations in the Czech Republic. Sb Lek 2000, 101, 59–65.
  4. Rennie KL, Jebb SA: Prevalence of obesity in Great Britain. Obes Rev 2005, 6, 11–12.
  5. Fact sheet EURO: The challenge of obesity in the WHO European Region, Copenhagen, Bucharest 2005, 13.
  6. Jarosz M. (ed.): National programme for the prevention of overweight, obesity and nom−communicable diseases through diet and improved physical activity, Pol−Health 2007–2016, Polish National Food Institute – IŻŻ, Warsaw 2006, pp 59.
  7. Li Z, Hong K, Wong K, Maxwell M, Heber D: Weight cycling in a very low−calorie diet programme has no effect on weight loss velocity, blood pressure and serum lipid profile. Diabetes Obes Metab 2007, 9, 379–385.
  8. Rosenbaum M, Leibel RL, Hirsch J: Obesity. N England J Med 1997, 337, 396–407.
  9. Pi−Sunyer FX: The obesity epidemic, pathophysiology and consequences of obesity. Obes Res 2002, 10, Suppl 2, 97S–104S.
  10. Jeffery RW, Utter J: The changing environment and population obesity in the United States. Obes Res 2003, 11, 12S–22S.
  11. Ravussin E, Gautier JF: Metabolic predictors of weight gain. Int J Obes Relat Metab Disord 2000, 23, 37–41.
  12. Pasarica M, Dhurandhar NV: Infectobesity, obesity of infectious origin. Adv Food Nutr Res 2007, 52, 61–102.
  13. Fernandez−Real JM, Ferri MJ, Vendrell J, Rivart W: Burden of infection and fat mass in healthy middle−aged men. Obesity (Silver Spring) 2007, 15, 245–252.
  14. Lyons MJ, Faust IM, Hemmes RB, Buskirk DR, Hirsch J, Zabriskie JB: A virally induced obesity syndrome in mice. Science 1982, 216, 82–85.
  15. Toplak H, Wascher TC, Weber K, Lauermann T, Reisinger EC, Bahadori B, Tilz GP, Haller EM: Increased prevalence of serum IgA Chlamydia antibodies in obesity. Acta Med Austriaca 1995, 22, 23–24.
  16. Dart AM, Martin JL, Kay S: Association between past infection with Chlamydia pneumoniae and body mass index, low−density lipoprotein particle size and fasting insulin. Int J Obes 2002, 26, 464–468.
  17. Cook PJ, Honeybourne D: Clinical aspects of Chlamydia pneumoniae infection. Presse Med 1995, 24, 278–282.
  18. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P: Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17, 2910–2913.
  19. Murray LJ, O’Reilly DPJ, Ong GML, O’Neill C, Evans AE, Bamford KB: Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile. Heart 1999, 81, 239–244.
  20. Nabipour I, Vahdat K, Jafari SM, Pazoki R, Sanjdideh Z: The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1, The Persian Gulf Healthy Heart Study. Cardiovasc Diabetol 2006, 5, 25–30.
  21. Pawlikowska M, Deptula W: Chlamydia, Chlamydophila and specific cellular immunity, Postepy Hig Med Dosw 2005, 59, 510–516.
  22. Witkiewicz W, Choroszy−Krol I, Gnus J, HauzerW, Skala J, Teryks−Wolyniec D, Frej−Madrzak M, Grzanka M, Zdzieblo I, Czerniejewski L: The detection of Chlamydia pneumoniae in the abdominal aortic aneurysm. Family Med & Primary Care Rev 2007, 9, 48–54.
  23. Lohman T, Roche A, Martorell R (eds.): Anthropometric standardization reference manual. Champaign, IL, Human Kinetics Books, 1991.
  24. Durnin JV, Womersley J: Body fat assessed from total body density and its estimation from skinfold thickness, measurements on 481 men and women aged 16 to 72 years. Br J Nutr 1974, 32, 77–97.
  25. Gutierrez J, Mendoza J, Fernandez F, Linares−Palomino J, Soto MJ, Maroto MC: ELISA test to detect Chlamydophila pneumoniae IgG. J Basic Microbiol 2002, 42, 13–18.
  26. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P: Chlamydia pneumoniae antibodies and serum lipids in Finish men, cross sectional study. BMJ 1997, 314, 1456–1457.
  27. Jedrychowski W, Maugeri U, Flak E, Mroz E, Bianchi I: Predisposition to acute respiratory infection among overweight preadolescent children, an epidemiologic study in Poland. Public Health 1998, 112, 189–195.
  28. Tanaka S, Inoue S, Isoda F, Waseda M, Ishihara M, Yamakawa T, Sugiyama A, Takamura Y, Okuda K: Impaired immunity in obesity, suppressed but reversible lymphocyte responsiveness. Int J Obes Relat Metab Disord 1993, 17, 631–636.
  29. Fontana L, Eagon JC, Colonna M, Klein S: Impaired mononuclear cell immune function in extreme obesity is corrected by weight loss. Rejuvenation Res 2007, 10, 41–46.
  30. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM: Obesity as a predictor of poor response to hepatitis B plasma vaccine. JAMA 1985, 254, 3187–3189.
  31. Simo Minana J, Gaztambide Ganuza M, Fernandez Millan P, Pena Fernandez M: Hepatitis B vaccine immunoresponsiveness in adolescents, a revaccination proposal after primary vaccination. Vaccine 1996, 14, 103–106.
  32. Ekesbo R, Nilsson PM, Lindholm LH, Persson K, Wadström T: Combined seropositivity for H. pylori and C. pneumoniae is associated with age, obesity and social factors. J Card Risk 2000, 7, 191–195.
  33. Thjodleifsson B, Olafsson I, Gislason D, Gislason T, Jogi R, Janson C: Infections and obesity: A multinational epidemiological study. Scand J Infect Dis 2007, doi: 10.1080/00365540701708293; url: http://dx.doi.org/10.1080/00365540701708293; 22 October 2007.